Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00005487 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi-Ethnic Study of Atherosclerosis (MESA)

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Amendment history

  1. Minor

    Study Status, Oversight, Study Description, Contacts/Locations, IPDSharing

    Re-verified, no change to tracked fields

    v13

  2. Notable

    Primary and study completion dates: Dec 2024 to Dec 2030

    Study Status, Oversight, Outcome Measures, IPDSharingv12

  3. Minor

    Study Status, Outcome Measures

    Re-verified, no change to tracked fields

    v11

  4. Notable

    Primary and study completion dates: Dec 2019 to Dec 2024

    Study Statusv10

  5. Notable

    Primary completion date: Aug 2015 to Dec 2019

    Enrollment target: estimated 6000 to confirmed 6418; Completion date: Jun 2009 to Dec 2019; Eligibility criteria expanded, about 11 words; and 2 more

    Show all 6 changes in this update
    • Notable Primary completion date: Aug 2015 to Dec 2019
    • Minor Enrollment target: estimated 6000 to confirmed 6418
    • Minor Completion date: Jun 2009 to Dec 2019
    • Minor Eligibility criteria expanded, about 11 words
      Show what changed
      NoCVD eligibilityfree criteriamen and women aged 45-84 at baseline from the four race/ethnic groups.
    • Minor Study description shortened, about 1,411 words
      Show what changed
      BACKGROUNDBackground: To further the study of the relationship between risk factors and atherosclerosis and to avoid the biases involved in relying solely on clinical disease outcomes, objective and unbiased measures of cardiovascular disease (CVD) have been introduced in NHLBI-initiated epidemiologic studies of CVD etio [...] MESA conceptwas derived from an NHLBI Task Force on Research in Epidemiology and Prevention convened in 1993, in which investigation of subclinical disease and its progression to clinical disease was recommended as a major focus offor future NHLBI population studies. This was f [...] [...]
    • Minor Publications: 172 to 79
      Show what changed
      Wang L, Jerosch-Herold M, Jacobs DR Jr, Shahar E, Folsom AR. Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2006 Feb 7;47(3):565-72. doi: 10.1016/j.jacc.2005.09.036. Epub 2006 Jan 18. Aboyans V, Criqui MH, M [...]

    Study Status, Study Description, Study Design, Outcome Measures, Eligibility, Contacts/Locations, Referencesv9

Show 7 earlier versions

  1. Minor

    Study Status

    Re-verified, no change to tracked fields

    v8

  2. Minor

    Study completion date changed from estimate of Aug 2015 to Jun 2009

    Study description expanded, about 22 words

    Show what changed: Study description
    [...] an increase in the overall well being of the US population. The study completion date listed in this record was obtained from the "Completed Date" entered in the Query View Report System (QVR).

    Study Status, Study Description, Referencesv7

  3. Minor

    Publications: 173 to 172

    Show what changed: Publications
    For a bibliography see http://mesa-nhlbi.org/

    Study Status, Referencesv6

  4. Minor

    Study Status, Sponsor/Collaborators

    Re-verified, no change to tracked fields

    v5

  5. Minor

    Enrollment target: 6000

    Primary completion date: Aug 2015; Publications: 80 to 173

    Show what changed: Publications
    Wang L, Jerosch-Herold M, Jacobs DR Jr, Shahar E, Folsom AR. Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2006 Feb 7;47(3):565-72. doi: 10.1016/j.jacc.2005.09.036. Epub 2006 Jan 18. Aboyans V, Criqui MH, M [...]

    Study Status, Sponsor/Collaborators, Conditions, Study Design, Eligibility, Contacts/Locations, Referencesv4

  6. Minor

    Completion date: Jan 2009 to Aug 2015

    Study Identification, Study Status, Study Design, Contacts/Locationsv3

  7. Minor

    Study Status

    Re-verified, no change to tracked fields

    v2

  1. Minor

    Study First Submitted

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
National Heart, Lung, and Blood Institute (NHLBI)
135 trials monitored
See 12 trials at risk
Diabetes
4,286 trials monitored
See 187 trials at risk
Stroke
3,289 trials monitored
See 142 trials at risk
Heart Disease
2,136 trials monitored
See 109 trials at risk
and 4 more diseases
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease (Bild DE et al., Am J Epidemiol 2002; 156(9):871-881). MESA consists of a diverse, community-based sample of an initial 6,814 men and women aged 45-84 years without known cardiovascular disease at baseline. Thirty-eight percent of the recruited participants were White, 28 percent African American, 22 percent Hispanic, and 12 percent of Chinese descent. Participants were recruited from six field centers across the United States: Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; New York, New York; and St. Paul, Minnesota. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and heart failure; for cardiovascular disease interventions; and for mortality. The first examination took place over two years, from July 2000 to July 2002, and has been followed by additional examinations. Participants have been contacted every 9 to 12 months throughout the study to assess and adjudicate clinical morbidity and mortality. The study was approved by the Institutional review boards at all participating institutions, and all participants gave written informed consent. In addition, informed consent was obtained for extensive data sharing (dbGaP) and genetic/omic studies, including candidate genes (NHLBI CARe), genome-wide scans (NHLBI SHARe), exome sequencing (NHLBI ESP) and, most recently, the NHLBI TOPMed program.
Trial Details
NCT Number NCT00005487
Lead Sponsor National Heart, Lung, and Blood Institute (NHLBI)
Conditions Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Coronary Disease, Stroke, Myocardial Infarction, Heart Failure +3 more
Enrollment 6,418 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov